Biocept products

As healthy and diseased tissue interact with the bloodstream, they release both cellular and genetic material into the circulation. These materials are referred to as “cell-free” DNA (cfDNA), and circulating tumor cells (CTCs). Conventional blood collection tubes contain only anti-coagulants, designed to prevent blood clotting. Over time, and without stabilization, nucleated blood cells lyse and release their genetic components into the blood. As a result, levels of cfDNA increase, which can prevent the detection and quantification of abnormal genetic material (i.e., circulating tumor DNA).

his kit detects BRAF V600 mutations in DNA derived from blood plasma or FFPE tissue sections to give insight into cancer characteristics and provide Biomarker status of tumors such as melanoma.

This kit detects EGFR mutations in DNA derived from blood plasma or FFPE tissue sections to give insight into cancer characteristics and provide Biomarker status of tumors such as non-small cell lung cancer.

Biocept’s Target Selector^™ molecular assay kits detect key oncogene mutations through the analysis of both Formalin-Fixed Paraffin-Embedded (FFPE) tissue gained from surgical biopsies as well as circulating tumor DNA (ctDNA) gained from blood-based liquid biopsies.  The EGFR pathway can include mutations that are among the most frequently evaluated biomarkers for lung cancer.

Combining Biocept’s Liquid Biopsy biomarker testing expertise with Oncomine^™ from Thermo Fisher Scientific’s next-generation sequencing and decision support resources.